表紙
市場調査レポート

世界の分子診断関連の提携状況:契約動向、企業、財務および予測

Global Molecular Diagnostics 2010-2016: Deal trends, players, financials and forecasts

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 315595
出版日 ページ情報 英文 447 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
世界の分子診断関連の提携状況:契約動向、企業、財務および予測 Global Molecular Diagnostics 2010-2016: Deal trends, players, financials and forecasts
出版日: 2016年09月01日 ページ情報: 英文 447 Pages
概要

当レポートでは、世界の分子診断関連市場における企業提携の締結動向とその内容(提携条件)について分析し、近年の企業提携/取引形成状況とその特徴、取引種類別・治療領域別・技術の種類別の詳細動向、平均的な取引条件、代表的な資本取引の概略、大手製薬企業/バイオテクノロジー企業の動向、近年の提携取引一覧とその内訳といった情報をお届けいたします。

エグゼクティブ・サマリー

第1章 イントロダクション

第2章 分子診断関連の取引形成の動向

  • イントロダクション
  • 過去数年間の分子診断関連の提携動向
  • 大手製薬企業による、分子診断関連の提携活動
  • 分子診断関連の提携:取引の種類別
  • 分子診断関連の提携:治療領域別
  • 公開されている資本取引の条件
    • 支払総額
    • 前払い金
    • マイルストーン払い
    • ロイヤルティ料率

第3章 代表的な提携取引

  • イントロダクション
  • 最上位の取引:金額別

第4章 大手製薬企業による、分子診断関連の提携活動

  • イントロダクション
  • 最も活発だった提携
  • 大口提携企業のプロファイル

第5章 分子診断関連の提携契約の一覧

  • イントロダクション
  • 分子診断関連の提携契約の一覧

第6章 分子診断関連取引:技術種類別

第7章 提携リソースセンター

  • オンライン提携
  • 提携動向
  • 関連資料

付録

  • 付録1:企業名順(A〜Z)
  • 付録2:治験段階別
    • 創薬
    • 前臨床
    • 第I相
    • 第II相
    • 第III相
    • 認証中
    • 上市済み
    • 処方(製剤)設計
  • 付録3:取引の種類別
    • 資産購入
    • 大手製薬企業のアウトライセンス
    • 共同開発
    • 共同研究開発(R&D)
    • 共同販売
    • 共同プロモーション
    • 共同研究開発合意(CRADA)
    • クロスライセンス
    • 開発
    • 流通
    • 株式購入
    • 評価
    • 助成金
    • 合弁事業
    • ライセンス
    • 訴訟
    • 製造
    • マーケティング
    • 物質移動
    • オプション
    • プロモーション
    • 研究
    • 調停
    • スピンアウト
    • 二次ライセンス
    • 供給
    • 技術移管
    • 契約終了
    • 保証
  • 付録4:治療領域別
  • 付録5:取引種類の定義

Wildwood Venturesについて

  • Current Partnering
  • Current Agreements
  • Current Partnering の最新レポート

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2102mol

Global Molecular Diagnostics Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the molecular diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Molecular Diagnostics Partnering 2010-2016 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.

The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 660 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Molecular Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Molecular Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Molecular Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Molecular Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Molecular Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Molecular Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Molecular Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Molecular Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Molecular Diagnostics technologies and products.

Key benefits

Global Molecular Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Molecular Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Molecular Diagnostics dealmakers since 2010
  • Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Molecular Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Molecular Diagnostics trends and structure of deals entered into by leading companies worldwide.

Molecular Diagnostics Partnering Terms and Agreements includes:

  • Trends in Molecular Diagnostics dealmaking in the biopharma industry since 2010
  • Analysis of Molecular Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Molecular Diagnostics deals
  • Access to Molecular Diagnostics contract documents
  • Leading Molecular Diagnostics deals by value since 2010
  • Most active Molecular Diagnostics dealmakers since 2010

In Global Molecular Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The Global Molecular Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 660 Molecular Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Molecular Diagnostics Partnering 2010-2016 report provides the reader with the following key benefits:

  • In-depth understanding of Molecular Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Molecular Diagnostics dealmakers since 2010
  • Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Molecular Diagnostics dealmaking

  • 2.1. Introduction
  • 2.2. Molecular Diagnostics partnering over the years
  • 2.3. Most active Molecular Diagnostics dealmakers
  • 2.4. Molecular Diagnostics partnering by deal type
  • 2.5. Molecular Diagnostics partnering by therapy area
  • 2.6. Deal terms for Molecular Diagnostics partnering
    • 2.6.1 Molecular Diagnostics partnering headline values
    • 2.6.2 Molecular Diagnostics deal upfront payments7
    • 2.6.3 Molecular Diagnostics deal milestone payments
    • 2.6.4 Molecular Diagnostics royalty rates

Chapter 3 - Leading Molecular Diagnostics deals

  • 3.1. Introduction
  • 3.2. Top Molecular Diagnostics deals by value

Chapter 4 - Most active Molecular Diagnostics dealmakers

  • 4.1. Introduction
  • 4.2. Most active Molecular Diagnostics dealmakers
  • 4.3. Most active Molecular Diagnostics partnering company profiles

Chapter 5 - Molecular Diagnostics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Molecular Diagnostics contracts dealmaking directory

Chapter 6 - Molecular Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Molecular Diagnostics deals by company A-Z
  • Appendix 2 - Molecular Diagnostics deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - Molecular Diagnostics deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty
  • Appendix 4 - Molecular Diagnostics deals by therapy area
  • Appendix 5 -Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Molecular Diagnostics partnering since 2010
  • Figure 2: Active Molecular Diagnostics dealmaking activity- 2010 to 2016
  • Figure 3: Molecular Diagnostics partnering by deal type since 2010
  • Figure 4: Molecular Diagnostics partnering by disease type since 2010
  • Figure 5: Molecular Diagnostics deals with a headline value
  • Figure 6: Molecular Diagnostics deals with an upfront value
  • Figure 7: Molecular Diagnostics deals with a milestone value
  • Figure 8: Molecular Diagnostics deals with a royalty rate value
  • Figure 9: Top Molecular Diagnostics deals by value since 2010
  • Figure 10: Most active Molecular Diagnostics dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top